Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data to Gain $17M in Private Stock Placement

NEW YORK, June 14 (GenomeWeb News) - Clinical Data today said it stands to gain $17 million from the sale of approximately 1.5 million shares and warrants of its common stock to certain undisclosed institutional and other investors.

 

The company did not discuss when it expects the transactions to close.

 

Clinical Data President and CEO Drew Fromkin said that the extra capital will strengthen his company's ability to commercialize molecular diagnostics; continue its Phase III clinical development of the antidepressant Vilazodone and help it spin out the vilazodone business into a new company called Precigen Therapeutics; and to enhance its genetic services and analysis business.

 

The company said it will also use some of the cash to pay for the restructuring it announced in March.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.